Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
miércoles, octubre 21
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Lantern Pharma Inc
LTRN
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$0.6564
0.0151
2.35%
Últ. Act.: Oct 20, 7:00 PM
$0.6858
0.0445
6.94%
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Informe de acciones
Privacy Manager
Lantern Pharma Financials
Lantern Pharma (LTRN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Lantern Pharma Q2 EPS $(0.57) Misses $(0.38) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.57) per share which missed the analyst consensus estimate of $(0.38) by 50 percent. This is a 42.5 percent decrease over losses of $(0.40) per share from the
Benzinga Newsdesk
PRO
Lantern Pharma Q1 EPS $(0.30) Beats $(0.36) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.30) per share which beat the analyst consensus estimate of $(0.36) by 16.67 percent. This is a 28.57 percent increase over losses of $(0.42) per share from
Benzinga Newsdesk
Earnings Scheduled For May 15, 2026
Benzinga Insights
PRO
Lantern Pharma Q4 EPS $(0.36) Beats $(0.46) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.36) per share which beat the analyst consensus estimate of $(0.46) by 21.74 percent. This is a 33.33 percent increase over losses of $(0.54) per share from
Benzinga Newsdesk
Earnings Scheduled For March 30, 2026
Benzinga Insights
PRO
Lantern Pharma Q3 EPS $(0.39) Beats $(0.54) Estimate
Lantern Pharma (NASDAQ:LTRN) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.54) by 27.78 percent. This is a 7.14 percent increase over losses of $(0.42) per share from the
Benzinga Newsdesk
